Intel Signals
Structured signals tracking regulatory shifts, pipeline moves, and market dynamics across life sciences.
Strongest planning baseline available, but not enacted law until formal adoption. The Council says formal steps will follow in the coming weeks. Our view is these dates are unlikely to shift — the political argument has been spent — but this is investor judgment, not legal fact.
Resolves the structural uncertainty that made MDAI compliance architecture impossible to finalise. Companies can now plan for an integrated MDR/IVDR + AI Act conformity assessment dossier — subject to final text and designation capacity. The tightened safety component definition may reduce high-risk classification for some assistive AI functions, but this is case-by-case and pending final text — not every clinical decision support tool escapes.
The extended deadlines buy time, but the infrastructure to certify MDAI products does not yet exist at scale. Companies that delay Notified Body engagement until closer to the deadline will likely hit the same queue problem regardless of when the legal obligation falls.
While high-risk deadlines moved out, these obligations are live within seven months. Portfolio companies operating generative AI systems should assess exposure based on output type and deployment context, especially where systems generate or manipulate image, audio, video or text content.
Directly relevant to investor diligence. Portfolio companies that have self-assessed as non-high-risk under Annex III cannot treat that as a compliance-free position. The registration requirement means the classification logic must be defensible and documented.
